Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model

被引：0

作者：

Zhang, Siwei ^{[1
]}

Xu, Huali ^{[1
]}

Yu, Xiaofeng ^{[1
]}

Wang, Yuchen ^{[1
]}

Sun, Fanfan ^{[1
]}

Sui, Dayuan ^{[1
]}

机构：

[1] Jilin Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changchun 130021, Jilin Province, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2015年 / 8卷 / 04期

关键词：

Simvastatin; oxidative stress; type 2 diabetic nephropathy; rat; CHRONIC KIDNEY-DISEASE; PLACEBO-CONTROLLED TRIAL; ACUTE-RENAL-FAILURE; OXIDATIVE STRESS; MECHANISMS; ASSOCIATION; INHIBITION; HEART; CTGF; HYPERGLYCEMIA;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The present study aims to study the possible renal protective effect of simvastatin in the development and progression of type 2 diabetic nephropathy. A rat model of T2DN was induced by high-fat diet together with single low-dose of streptozotocin. The diabetic rats were either given treatment or vehicle control for 13 weeks to develop nephropathy. At the end of treatment, parameters of renal function were determined. Kidney samples were collected for histological studies and generated homogenates for biochemical analysis. In T2DN rats, severe hyperglycemia was developed, FBG were markedly elevated. Diabetes induced significant alterations in renal structure, such as severe reduction of glomerular tufts, increase in Bowman's spaces, thickening of GBM. In addition, and SCr, UAER and BUN are elevated, accompanied with reduction in UCr and CCr, indicating obvious renal failure. On the other hand, endogenous antioxidants SOD, GSH-Px were reduced, whereas MDA was increased. However, treatment of T2DN rats with simvastatin restored renal changes in different aspects. Our results showed that STZ-induced T2DN could be attenuated by simvastatin. The renoprotective effects of simvastatin was indicated by improvements in kidney function parameters, and was attributed by its lipid-lowering effect as well as its anti-oxidative stress, anti-inflammatory properties without having noticeable influence on glycemic control. Simvastatin ameliorates low-dose Streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model.

引用

页码：6388 / 6396

页数：9

共 40 条

[1]

Abe H, 2011, HISTOL HISTOPATHOL, V26, P531, DOI 10.14670/HH-26.531

[2]

Akbas EM, 2014, INT J CLIN EXP MED, V7, P1794

[3] Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease [J].

Almquist, Tora ;

Jacobson, Stefan H. ;

Mobarrez, Fariborz ;

Nasman, Per ;

Hjemdahl, Paul .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (03) :276-284

[4] Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy [J].

Athyros, Vasilios G. ;

Mitsiou, Eydoxia K. ;

Tziomalos, Konstantinos ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (05) :723-730

[5] Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease [J].

Baigent, C. ;

Landray, M. ;

Reith, C. ;

Dasgupta, T. ;

Emberson, J. ;

Herrington, W. ;

Lewis, D. ;

Mafham, M. ;

Collins, R. ;

Baigent, C. ;

Landray, M. ;

Bray, C. ;

Chen, Y. ;

Baxter, A. ;

Young, A. ;

Hill, M. ;

Knott, C. ;

Cass, A. ;

Feldt-Rasmussen, B. ;

Fellstroem, B. ;

Grobbee, R. ;

Groenhagen-Riska, C. ;

Haas, M. ;

Holdaas, H. ;

Hooi, L. S. ;

Jiang, L. ;

Kasiske, B. ;

Krairittichai, U. ;

Levin, A. ;

Massy, Z. ;

Tesar, V. ;

Walker, R. ;

Wanner, C. ;

Wheeler, D. ;

Wiecek, A. ;

Dasgupta, T. ;

Lewis, D. ;

Mafham, M. ;

Majoni, W. ;

Reith, C. ;

Simpson, D. ;

Strony, J. ;

Musliner, T. ;

Agodoa, L. ;

Armitage, J. ;

Chen, Z. ;

Craig, J. ;

de Zeeuw, D. ;

Gaziano, M. .

AMERICAN HEART JOURNAL, 2010, 160 (05) :785-U28

[6] Chronic kidney disease growth factors in renal fibrosis [J].

Boor, Peter ;

Floege, Juergen .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2011, 38 (07) :391-400

[7] In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs) - Novel inhibition of post-Amadori glycation pathways [J].

Booth, AA ;

Khalifah, RG ;

Todd, P ;

Hudson, BG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (09) :5430-5437

[8] Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm [J].

Branchetti, Emanuela ;

Poggio, Paolo ;

Sainger, Rachana ;

Shang, Eric ;

Grau, Juan B. ;

Jackson, Benjamin M. ;

Lai, Eric K. ;

Parmacek, Michael S. ;

Gorman, Robert C. ;

Gorman, Joseph H. ;

Bavaria, Joseph E. ;

Ferrari, Giovanni .

CARDIOVASCULAR RESEARCH, 2013, 100 (02) :316-324

[9] CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes:: a potential role in heart fibrosis [J].

Chen, MM ;

Lam, A ;

Abraham, JA ;

Schreiner, GF ;

Joly, AH .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (10) :1805-1819

[10]

Choudhary Nikhil, 2008, Iran J Kidney Dis, V2, P72

← 1 2 3 4 →